Mature B-Cell Malignancies clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

    open to eligible people ages 18 years and up

    The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.

    Los Angeles, California and other locations

Last updated: